CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE

Scientific and Medical Research Funding Working Group

Recommendations for Alternate Membership
Independent Citizen's Oversight Committee Meeting
Sacramento, California
June 6, 2005

Ian D. Duncan, BVMS, PhD, FRCVS, FRCPath
Dr. Duncan is Professor of Neurology in the Department of Medical Sciences at the University of Wisconsin-Madison School of Veterinary Medicine and a founding member of the Scientific Advisory Boards of the Myelin Project and Hunter's Hope, both foundations established to support research on diseases of the central nervous system. Elected Councilor for the American Society for Neurochemistry in 2001, he is on the editorial board of the journals *Neuron Glia Biology* and the *International Journal of Molecular Medicine*, and has extensive service as a grant reviewer for federal agencies such as the National Institutes of Health and the National Science Foundation, for research foundations including the National Multiple Sclerosis Society, the Myelin Project, the New York Academy of Sciences, and the Spinal Cord Research Foundation, and for numerous agencies abroad such as the Wellcome Trust, the Biotechnology and Biological Sciences Research Council in the UK, the International Human Frontier Science Program, the Medical Research Council of Canada, the Canadian MS Society, the Australian MS Society, and the Dutch MS Society. Dr. Duncan's research focuses on the use of embryonic stem cell-derived progenitors in brain repair. His main interest is to investigate the potential of glial cell transplantation as a therapeutic approach to repair dysfunctions in myelination in the nervous system.

Arthur W. Nienhuis, MD:
St. Jude Professor of Pediatrics and Medicine at the University of Tennessee, Dr. Nienhuis is also a member of the Division of Experimental Hematology in the Department of Hematology-Oncology at St. Jude's Research Hospital in Memphis, TN. He is a past Director of St. Jude's Hospital and former Chief of the Clinical Hematology Branch of the National Heart Lung Blood Institute at the National Institutes of Health. A member of the Institute of Medicine, the National Academy of Sciences and the National Cancer Advisory Board, he served as President of the American Society of Hematology in 1994 and received one of the most distinguished awards in the field of hematology, the Stratton Medal in 1998. He chaired the Hematology Board of the American Board of Internal Medicine, served as Editor of the Journal of the American Society of Hematology (*Blood*) and currently sits on the Editorial Boards of the *Journal of Clinical Investigation*, *Molecular Therapy* and *Human Gene Therapy*. His research focus is on stem cell targeted gene therapy for the treatment of hemoglobin disorders and immunodeficiencies.

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE

David T. Scadden, MD
Dr. Scadden, Professor of Medicine at Harvard Medical School, is Director of the Massachusetts General Hospital's (MGH) Center for Regenerative Medicine and Technology and Co-Director of the Harvard Stem Cell Institute. A board-certified hematologist/oncologist, Dr. Scadden serves on the Executive Committee of the Harvard Medical School Division of AIDS and is Chief of the Hematologic Malignancies Program at the MGH Cancer Center. He is a member of the National Cancer Institute's Board of Scientific Counselors at the National Institutes of Health and chairs the NCI-sponsored AIDS Malignancy Consortium, a cooperative effort among national and international AIDS treatment centers to develop new approaches to the understanding and treatment of immunodeficiency-related malignant disease. Regarded as a leader in hematopoietic stem cell biology, Dr. Scadden's research is on blood cell development and the use of blood cells as therapy. Together with Dr. Douglas Melton, he leads a Harvard-wide effort in stem cell research to develop treatments for chronic, debilitating disease. Dr. Scadden currently serves as an Associate Editor for the journal *Blood*, and as a member of the editorial boards for the journals *Experimental Hematology* and *Stem Cells*.

Yair Reisner, PhD
A renowned expert in transplantation technology, Dr. Reisner holds the Henry Drake Chair of Immunology at the Weizman Institute of Science in Rehovat (rihō'vōt), Israel and serves as an Associate Editor for the Journal for Experimental Hematology. Dr. Reisner has pioneered and popularized techniques for bone marrow transplantation with partially matched donor tissue. In 1993, he founded XTL Biopharmaceuticals Ltd. which developed human monoclonal antibodies for the treatment of hepatitis, and served on its Scientific Advisory Board. Among the many awards that he has received are the Daniele Chianelli Award for his work on haploidentical mismatched bone marrow transplantation, the Maharshi Sushruta Award, and the Mortimer M. Bortin Award for Outstanding Research in Blood and Marrow Transplantation.

Frank J. Rauscher, III, PhD
Dr. Rauscher, Professor and Chairman of the Molecular Genetics Program at the Wistar Institute in Philadelphia also serves as Associate Director of Research Programs and Deputy Director of the Wistar Institute Cancer Center. He is a member of the Institute for Human Gene Therapy at the University of Pennsylvania School of Medicine where he is an Adjunct Professor of Genetics. Dr. Rauscher has extensive service as a grant reviewer for Study Sections at the National Institutes of Health and other agencies and foundations. He is Editor-in-Chief of *Cancer Research* and is well known for his research in gene regulation, molecular oncology, and his work on DNA-binding proteins.

James Roberts, MD, PhD

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE

Dr. Roberts is Director of the Division of Basic Sciences and Senior Vice President of the Fred Hutchinson Cancer Research Center, and is an investigator of the Howard Hughes Medical Institute. Dr. Roberts' laboratory works on pathways that control the proliferation of mammalian cells, and how those pathways are misregulated in tumors.

R. Paul Robertson, MD

Dr. Robertson is President and Scientific Director of the Pacific Northwest Research Institute and Professor of Medicine and Pharmacology at the University of Washington. He is a member of the American Society for Clinical Investigation and serves on the National Board of Directors for the American Diabetes Association. Dr. Robertson has been Editor-in-Chief of *Diabetes*, the research journal of the American Diabetes Association, and is currently on the Editorial Board of the *Journal of Biological Chemistry*. He has chaired two study sections at the NIH, the Metabolism Study Section as well as the Special Grants Committee of the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). Dr. Robertson's primary interest is on beta cell function. His current research focus is on studies of glucose toxicity of the beta cell in patients with Type II diabetes, and islet transplantation in patients with Type I diabetes. Dr. Robertson has received national recognition for his research on diabetes. Among his many honors is the endowed Pennock Chair for Diabetes Research at the University of Minnesota and the Albert Renold Award of the American Diabetes Association.

Michael R. Rosen, MD

Dr. Rosen is the Gustavus A. Pfeiffer Professor of Pharmacology, Professor of Pediatrics and Director of the Center for Molecular Therapeutics in the Department of Pharmacology at the College of Physicians and Surgeons of Columbia University. Dr. Rosen's current research focus is on gene and cell-based therapies for cardiac rhythm disturbances. His research aims to develop biological pacemakers for these conditions. For his scholarship in the field of cardiac electrophysiology, he has received the American Heart Association's Award of Merit and the Chairman's Award, the Einthoven Award on the 100th anniversary of Einthoven's invention of the electrocardiogram, and the 2004 Distinguished Scientist Award of the Heart Rhythm Society. He currently serves on the editorial boards of the journal *Circulation* and the *Journal of Cardiovascular Electrophysiology*, and is Editor-in-Chief of the *Journal of Cardiovascular Pharmacology*. Dr. Rosen has also served on and chaired numerous review panels at the NIH, the AHA and the New York Heart Association.

Catherine Verfaillie, MD

Dr. Verfaillie is currently Professor of Medicine in the Division of Hematology, Oncology, and Transplantation and Director of the Stem Cell Institute at the University of Minnesota. Recognized world-wide for her research in stem cell biology and her discovery of Multipotent Adult Progenitor Cells, a unique class of adult stem cells with the ability to develop into all the major classes of tissue and cells types, Dr. Verfaille holds the Anderson Chair in Stem Cell Biology, the Tulloch Chair in Stem Cell Biology, Genetics and Genomics, and the McKnight's Presidential Chair in Stem Cell Biology. [In 2001, she was named by U.S. World and News

Report as one of the ten Innovators of the year.] Her research focuses on the regulation of proliferation, differentiation and lineage commitment of hematopoietic stem cells and other multipotent stem cells.